tiprankstipranks
Advertisement
Advertisement

HALO Stock Latest News

Halozyme names Darren Snellgrove as CFO
The FlyHalozyme names Darren Snellgrove as CFO
4d ago
JNJ
HALO
Halozyme Appoints New Chief Financial Officer to Drive Growth
PremiumCompany Announcements
Halozyme Appoints New Chief Financial Officer to Drive Growth
4d ago
8K
HALO
Halozyme price target raised to $95 from $90 at H.C. Wainwright
PremiumThe Fly
Halozyme price target raised to $95 from $90 at H.C. Wainwright
5d ago
HALO
Halozyme price target raised to $96 from $94 at Morgan Stanley
PremiumThe Fly
Halozyme price target raised to $96 from $94 at Morgan Stanley
13d ago
HALO
Halozyme: Underappreciated, Durable Royalty-Driven Growth Beyond 2028 Supports Buy Rating
PremiumRatings
Halozyme: Underappreciated, Durable Royalty-Driven Growth Beyond 2028 Supports Buy Rating
25d ago
HALO
Halozyme enters global global collaboration and license agreement with Vertex
PremiumThe FlyHalozyme enters global global collaboration and license agreement with Vertex
27d ago
HALO
VRTX
Halozyme Names David Ramsay Interim Chief Financial Officer
Premium
Company Announcements
Halozyme Names David Ramsay Interim Chief Financial Officer
2M ago
8K
HALO
Halozyme names David Ramsay as Interim CFO
Premium
The Fly
Halozyme names David Ramsay as Interim CFO
2M ago
HALO
Halozyme price target raised to $94 from $78 at Morgan Stanley
PremiumThe Fly
Halozyme price target raised to $94 from $78 at Morgan Stanley
2M ago
HALO
Halozyme price target raised to $90 from $75 at Benchmark
PremiumThe Fly
Halozyme price target raised to $90 from $75 at Benchmark
2M ago
HALO
Halozyme price target raised to $75 from $65 at Wells Fargo
PremiumThe Fly
Halozyme price target raised to $75 from $65 at Wells Fargo
2M ago
HALO
Halozyme Earnings Call Highlights Royalty-Fueled Growth
PremiumCompany Announcements
Halozyme Earnings Call Highlights Royalty-Fueled Growth
2M ago
HALO
Halozyme: Strong Royalty Momentum and Underappreciated Multi‑Year Earnings Power Support Buy Rating
PremiumRatingsHalozyme: Strong Royalty Momentum and Underappreciated Multi‑Year Earnings Power Support Buy Rating
3M ago
HALO
Halozyme reaffirms FY26 non-GAAP EPS view $7.75-$8.25, consensus $8.18
Premium
The Fly
Halozyme reaffirms FY26 non-GAAP EPS view $7.75-$8.25, consensus $8.18
3M ago
HALO
Halozyme reports Q4 EPS 24c vs. $1.26 last year
Premium
The Fly
Halozyme reports Q4 EPS 24c vs. $1.26 last year
3M ago
HALO
Genmab sees 2026 revenue $4.065B-$4.395B, consensus $4.13B
PremiumThe Fly
Genmab sees 2026 revenue $4.065B-$4.395B, consensus $4.13B
3M ago
JNJ
GMAB
HALO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
HALO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
HALO
Halozyme sees FY26 EPS $7.75-$8.25, consensus $8.21
PremiumThe Fly
Halozyme sees FY26 EPS $7.75-$8.25, consensus $8.21
3M ago
HALO
Halozyme raises FY25 revenue view to $1.39B-$1.4B from $1.3B-$1.38B
PremiumThe Fly
Halozyme raises FY25 revenue view to $1.39B-$1.4B from $1.3B-$1.38B
3M ago
HALO
Leerink views ‘major deal’ on Entyvio as positive for Halozyme
PremiumThe FlyLeerink views ‘major deal’ on Entyvio as positive for Halozyme
4M ago
TAK
HALO
Halozyme: ENHANZE Platform Partnerships in Immunology and Obesity Drive Underappreciated Royalty Upside and Support Buy Rating
Premium
Ratings
Halozyme: ENHANZE Platform Partnerships in Immunology and Obesity Drive Underappreciated Royalty Upside and Support Buy Rating
4M ago
HALO
Halozyme price target raised to $90 from $79 at TD Cowen
Premium
The Fly
Halozyme price target raised to $90 from $79 at TD Cowen
4M ago
HALO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >